Expression of the human poliovirus receptor (CD155) as an unfavorable prognostic factor for the choroid melanoma
https://doi.org/10.18027/2224-5057-2024-029
Abstract
Aim: to characterize CD155 expression in primary choroidal melanoma cells and determine its prognostic value for survival.
Material and methods: 68 patients with primary choroidal melanoma were included. The levels and patterns of CD155 expression in tumor tissues were studied using immunohistochemical method. Regression analysis was performed to identify independent factors predicting the course of the disease.
Results: in 51 % of cases, membrane expression of CD155 was registered in choroidal melanoma cells. In the group of tumors with any type of membrane expression of CD155, the signs of poor prognosis were statistically significantly more common. Membrane expression of CD155 was found to be an independent prognostic factor for the development of distant metastases according to multivariate regression analysis (RR 3.7 95 % CI 1.3–10.4, p = 0.005), as well as for death from choroidal melanoma (RR 3.2 95 %CI 1.2–8.3, p = 0.009).
Conclusion: the expression patterns of CD155 in primary choroidal melanoma were studied. It was found that the presence of membrane expression of CD155 was associated with an increased risk of choroid melanoma progression by 3.7 times and death by 3.2 times.
Supporting agencies: The article was prepared without sponsorship.
About the Authors
I. Yu. Zherka
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Competing Interests:
Belarus
Zherka Iryna Yurevna
Lesnoy, Minsk 223040
Competing Interests:
The authors declare that there are no possible conflicts of interest.
D. A. Davydov
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Competing Interests:
Belarus
Davydov Denis Aleksandrovich
Lesnoy, Minsk 223040
Competing Interests:
The authors declare that there are no possible conflicts of interest.
E. P. Shupilova
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Competing Interests:
Belarus
Shupilova Ekaterina Pavlovna
Lesnoy, Minsk 223040
Competing Interests:
The authors declare that there are no possible conflicts of interest.
A. F. Mahilyanchyk
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Competing Interests:
Belarus
Mogilyanchik Aleksandra Fedorovna
Lesnoy, Minsk 223040
Competing Interests:
The authors declare that there are no possible conflicts of interest.
A. S. Portyanko
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Competing Interests:
Belarus
Portyanko Anna Sergeevna
Lesnoy, Minsk 223040
Competing Interests:
The authors declare that there are no possible conflicts of interest.
References
1. Jager M.J., Shields C.L., Cebulla C.M., et al. Uveal melanoma. Nat Rev Dis Primers 2020;6(1):24. https://doi.org/10.1038/s41572-020-0158-0
2. Algazi A.P., Tsai K.K., Shoushtari A.N., et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016;122(21):3344–3353. https://doi.org/10.1002/cncr.30258
3. Dhillon S. Tebentafusp: First Approval. Drugs 2022;82(6):703–710. https://doi.org/10.1007/s40265-022-01704-4
4. Petrausch U., Martus P., Tönnies H., et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008;22(8):997–1007. https://doi.org/10.1038/sj.eye.6702779
5. Onken M.D., Worley L.A., Tuscan M.D., Harbour J.W. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12(4):461–468. https://doi.org/10.2353/jmoldx.2010.090220
6. Aaberg T.M. Jr, Cook R.W., Oelschlager K., et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol 2014;8:2449–60. https://doi.org/10.2147/OPTH.S70839
7. Carvajal R.D., Sacco J.J., Jager M.J., et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol 2023;20(2):99–115. https://doi.org/10.1038/s41571-022-00714-1
8. Onken M.D., Worley L.A., Char D.H., et al. Collaborative ocular Oncology Group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119(8):1596–1603. https://doi.org/10.1016/j.ophtha.2012.02.017
9. Mezheyeuski A., Backman M., Mattsson J., et al. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine 2023;88:104452. https://doi.org/10.1016/j.ebiom.2023.104452
10. Bakhoum M.F., Esmaeli B. Molecular characteristics of uveal melanoma: Insights from the Cancer Genome Atlas (TCGA) project. Cancers (Basel) 2019;11(8):1061. https://doi.org/10.3390/cancers11081061
11. Zherka I., Gulenko O., Ruksha K., et al. Influence of tumor-infiltrating T-cells’ characteristics on the survival of patients with primary choroid melanoma. ESMO Open 2024;9(1s2):P.1. https://doi.org/10.1016/j.esmoop.2024.102528
12. Zherka I., Gulenko O., Ruksha K., et al. Influence of tumor immune infiltrate characteristics on survival rates of patients with choroid melanoma. ESMO Open 2023;8(1s3):P.1. https://doi.org/10.34883/PI.2023.11.1.015
13. Chauvin J.M., Zarour H.M. TIGIT in cancer immunotherapy. J Immunother Cancer 2020;8(2):e000957. https://doi.org/10.1136/jitc-2020-000957
14. Tang W., Chen J., Ji T., Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis 2023;14(7):466. https://doi.org/10.1038/s41419-023-05961-3
15. Tannir N.M., Forero-Torres A., Ramchandren R., et al. Phase I dose escalation study of SGN-75 in patients with CD70-positive relapsed/ refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 2014;32(6):1246–57. https://doi.org/10.1007/s10637-014-0151-0
16. Folberg R., Chen X., Boldt H.C., Pe’er J., et al. Microcirculation patterns other than loops and networks in choroidal and ciliary body melanomas. Ophthalmology 2001;108(5):996–1001. https://doi.org/10.1016/s0161-6420(01)00541-3
17. Zherka I., Gulenko O., Ruksha K., et al. Influence of Tumor Immune Infiltrate Characteristics on Survival Rates of Patients with Choroid Melanoma. Eurasian Journal of Oncology 2023;11(1):47–59 (In Russ.). https://doi.org/10.34883/Pl.2023/11/1/015
18. Stamm H., Klingler F., Grossjohann E.M., et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene 2018;37(39):5269–80. https://doi.org/10.1038/s41388-018-0288-y
19. Nishiwada S., Sho M., Yasuda S., et al. Clinical signifcance of CD155 expression in human pancreatic cancer. Anticancer Res 2015;35(4):2287–97
20. Morimoto S., Kanno Y., Tanaka Y., et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol 2000;164(8):4097–104. https://doi.org/10.4049/jimmunol.164.8.4097
21. Shang B., Liu Y., Jiang S.J., Liu Y. Prognostic value of tumor-infiltrating FoxP3 + regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015;5:15179. https://doi.org/10.1038/srep15179.
22. Borst J., Hendriks J., Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005;17(3):275–81. https://doi.org/10.1016/j.coi.2005.04.004
23. Tesselaar K., Xiao Y., Arens R., et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003;170(1):33–40. https://doi.org/10.4049/jimmunol.170.1.33
24. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3(8):609–20. https://doi.org/10.1038/nri1148
25. Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030
26. Stanietsky N., Simic H., Arapovic J., et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci 2009;106(42):17858–17863. https://doi.org/10.1073/pnas.0903474106.
Review
For citations:
Zherka I.Yu., Davydov D.A., Shupilova E.P., Mahilyanchyk A.F., Portyanko A.S. Expression of the human poliovirus receptor (CD155) as an unfavorable prognostic factor for the choroid melanoma. Malignant tumours. 2024;14(4):70-76. (In Russ.) https://doi.org/10.18027/2224-5057-2024-029
Views:
163
Email this article 